Keymed Biosciences announced that the first patient has been dosed in the Phase I trial of CM350. CM350 is a GPC3xCD3 bispecific antibody developed by the Company for the treatment of solid tumors. The phase I trial is being conducted to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of CM350 in patients with solid tumors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.6 HKD | -1.66% | +2.01% | -27.49% |
30/04 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
29/04 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.49% | 1.26B | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350